Mostrar el registro sencillo del ítem
dc.contributor.author | Prota, Gennaro | |
dc.contributor.author | Gileadi, Uzi | |
dc.contributor.author | Rei, Margarida | |
dc.contributor.author | Lechuga-Vieco, Ana Victoria | |
dc.contributor.author | Chen, Ji-Li | |
dc.contributor.author | Galiani, Silvia | |
dc.contributor.author | Bedard, Melissa | |
dc.contributor.author | Lau, Vivian Wing Chong | |
dc.contributor.author | Fanchi, Lorenzo F | |
dc.contributor.author | Artibani, Mara | |
dc.contributor.author | Hu, Zhiyuan | |
dc.contributor.author | Gordon, Siamon | |
dc.contributor.author | Rehwinkel, Jan | |
dc.contributor.author | Enriquez, Jose Antonio | |
dc.contributor.author | Ahmed, Ahmed A | |
dc.contributor.author | Schumacher, Ton N | |
dc.contributor.author | Cerundolo, Vincenzo | |
dc.date.accessioned | 2022-03-03T10:55:02Z | |
dc.date.available | 2022-03-03T10:55:02Z | |
dc.date.issued | 2020-05 | |
dc.identifier.citation | Cancer Immunol Res. 2020; 8(5):685-697 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/13715 | |
dc.description.abstract | Epitopes derived from mutated cancer proteins elicit strong antitumor T-cell responses that correlate with clinical efficacy in a proportion of patients. However, it remains unclear whether the subcellular localization of mutated proteins influences the efficiency of T-cell priming. To address this question, we compared the immunogenicity of NY-ESO-1 and OVA localized either in the cytosol or in mitochondria. We showed that tumors expressing mitochondrial-localized NY-ESO-1 and OVA proteins elicit significantdly higher frequencies of antigen-specific CD8+ T cells in vivo. We also demonstrated that this stronger immune response is dependent on the mitochondrial location of the antigenic proteins, which contributes to their higher steady-state amount, compared with cytosolic localized proteins. Consistent with these findings, we showed that injection of mitochondria purified from B16 melanoma cells can protect mice from a challenge with B16 cells, but not with irrelevant tumors. Finally, we extended these findings to cancer patients by demonstrating the presence of T-cell responses specific for mutated mitochondrial-localized proteins. These findings highlight the utility of prioritizing epitopes derived from mitochondrial-localized mutated proteins as targets for cancer vaccination strategies. | es_ES |
dc.language.iso | eng | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Antigens, Neoplasm | es_ES |
dc.subject.mesh | CD4-Positive T-Lymphocytes | es_ES |
dc.subject.mesh | CD8-Positive T-Lymphocytes | es_ES |
dc.subject.mesh | Cancer Vaccines | es_ES |
dc.subject.mesh | Cell Line, Tumor | es_ES |
dc.subject.mesh | Disease Models, Animal | es_ES |
dc.subject.mesh | Epitopes | es_ES |
dc.subject.mesh | Mice | es_ES |
dc.subject.mesh | Mice, Inbred C57BL | es_ES |
dc.subject.mesh | Mice, Knockout | es_ES |
dc.subject.mesh | Mice, Transgenic | es_ES |
dc.subject.mesh | Mitochondrial Proteins | es_ES |
dc.subject.mesh | Neoplasms | es_ES |
dc.title | Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 32205315 | es_ES |
dc.format.volume | 8 | es_ES |
dc.format.number | 5 | es_ES |
dc.format.page | 685-697 | es_ES |
dc.identifier.doi | 10.1158/2326-6066.CIR-19-0467 | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2326-6074 | es_ES |
dc.identifier.journal | Cancer immunology research | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Genética Funcional del Sistema de Fosforilación Oxidativa | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.rights.accessRights | open access | es_ES |